1) As expected, AI giant Anthropic (ANT) successfully went public today. Shares are up around 20% from their IPO price of $83, giving the company a mind-boggling $1.3 trillion market cap.

Studies show that buying companies when they go public is one of the worst investments you can make. I've never done so – and I'm not going to start today.

However, as I wrote in four e-mails over the past three weeks, Anthropic is an impressive company that's growing extremely rapidly. So I'd never short it.

Here's my main advice about Anthropic – and Nvidia (NVDA), which I wrote about yesterday... You don't have to be a hero.

Do you really think you have an edge over the 10 bazillion other investors (and supercomputers) looking at these companies and their stocks?

Instead, your time is better spent looking outside the tech sector and finding companies with long growth runways that you can buy at fair prices. If the company is good enough, the stock doesn't even need to be cheap by traditional valuation metrics.

A good example I've written about recently is Casey's General Stores (CASY), which is up 17% since I took a "fresh look" at it on September 24.

Another is Eli Lilly (LLY), which is up 23% since we recommended it in our June issue of our flagship newsletter, Stansberry's Investment Advisory. If you're not already subscribed, you can do so by clicking here.

2) Speaking of Lilly, GLP-1 weight-loss drugs have been on my mind recently. I've been hearing more stories of their life-changing benefits, as well as various media reports about them...

I accompanied my parents to my dad's appointment yesterday at Dartmouth Hitchcock Medical Center, and the woman checking us in happened to mention that she has lost 100 pounds. She said she has been taking Lilly's GLP-1, Zepbound, for two years with no side effects. But she hasn't reached her desired weight yet because she has plateaued.

I told her to keep an eye on retatrutide, Lilly's upcoming new weight-loss injectable. I said, "It's like Zepbound on steroids because it's a triple agonist. The average person loses around 20% of their body weight on Zepbound, but 29% on retatrutide in Lilly's trials. It's not approved yet, but should be soon."

Last weekend, I was with one of my cousins who wants to lose 100 pounds. He started Zepbound six weeks ago and has already lost 20 pounds, with no side effects. And his blood pressure is down to 124/76, below the 140-to-150 level he has been at his entire life.

He's also hoping it'll help with his sleep apnea, which requires him to wear a CPAP machine at night. He's going to ask his doctor if he can try going without the machine, as the U.S. Food and Drug Administration ("FDA") has approved Zepbound to treat sleep apnea.

These are just two more stories of the dozens I've heard from family, friends, and acquaintances – backed up by countless studies – that GLP-1s are miracle drugs transforming the lives of millions of people.

Yet tens of millions more people who would benefit from these drugs aren't on them, for three main reasons...

First is cost. For people whose health plans won't cover these drugs, the price tag is substantial.

Novo Nordisk's (NVO) semaglutide/Ozempic costs $150 per month for new patients for four weekly injections. The daily semaglutide/Wegovy pill costs the same. And Lilly's better drug, tirzepatide/Zepbound, costs $299 per month for a 2.5 mg starter dose, $399 for 5 mg, and $449 for 7.5 mg to 15 mg (the maximum dose).

(Note that roughly 4 million Americans on Medicare who are overweight/obese and have a qualifying comorbidity such as cardiovascular disease, prediabetes, stroke, or uncontrolled high blood pressure now qualify for certain GLP-1s for only a $50 copay per month.)

I've read stories that many people are buying tirzepatide on the black market for as little as $2 per mg – meaning if they're taking a 7.5 mg weekly dose, the cost is only $60 per month. To be clear, I'm not recommending this course of action. It's risky. But people are doing it.

Second, many people are choosing not to take these drugs due to shame. They feel like it's cheating because they should be able to control their appetite on their own. I see this especially among women, as this Harper's Bazaar article captures: Ozempic Is Wreaking Havoc on Mother-Daughter Relationships. Excerpt:

... the GLP revolution has tapped into some of our deepest cultural anxieties around weight and body image, shaking up friendships and transforming marriages. Perhaps nowhere has it caused more friction than between mothers and daughters. After all, many of us got our most deeply ingrained ideas about beauty, but also self-control and appetite, from our mothers, who got them from their mothers, and so on. Now that a simple injection may be able to control what a lifelong struggle could not, mothers and daughters alike are wrestling with the implications – and a wealth of emotion is rising to the surface.

Zoë Bisbing, a therapist in New York City who focuses on body image, sees the same scenarios over and over in her practice. There are the women in midlife whose 70- or 80-year-old mothers are on a GLP-1 and have made it the center of family discussions. "I hear a lot from women who are like, 'Yep, the grandmas are on it and can't stop talking about it,'" Bisbing says. There are the young adults whose parents are pressuring them to take one of the drugs – sometimes even offering to pay for them – in a way that recalls a childhood spent being dragged to Weight Watchers. Some women don't even want their mothers to know they're on the meds. "It feels like something that will please their moms," Bisbing says, "and they don't want to please their moms."

When one member of a family suddenly, dramatically loses weight, the sense of betrayal can be intense...

Reading stories like this drives me crazy.

If a loved one were suffering from cancer, heart disease, high blood pressure, diabetes, long COVID, etc., and there was a new class of miracle drugs that greatly mitigated, if not eliminated, the disease... why would they hide the fact that they were taking the drug? And why would anyone look down on them for doing so?

I have high cholesterol, resulting in high plaque in my arteries. My calcium score is in the bottom 7% for my age – it's genetic, independent of my diet and exercise. As a result, I take a baby aspirin every other day, a monoclonal antibody injection (Repatha) every other week, and a 1 mg microdose of retatrutide every week (which allowed me to go off a daily 5 mg Crestor pill).

Do I feel shame that I have this disease? Or that I take medication to combat it? And does anyone look down on me for this? Of course not!

What's so hard to understand that obesity is a chronic, long-term disease? It is not because 72% of overweight/obese Americans are lazy, weak, and/or lack willpower.

Yet the shame and stigma persist...

The final reason many people avoid these drugs is scary but misleading media articles. The latest was in the Washington Post earlier this week, featuring a man who's suing Novo Nordisk...

He was taking Ozempic and went blind due to nonarteritic anterior ischemic optic neuropathy ("NAION"), which occurs when blood flow to the optic nerve is disrupted, causing sudden loss of vision: The serious complications of GLP-1s that few may know about. Excerpt:

Four months after Engel started taking Ozempic to treat his diabetes, he woke one morning unable to see out of his right eye. His ophthalmologist told him the damage was permanent but couldn't explain what caused it. No one suggested Ozempic might be involved, so Engel kept taking the GLP-1 drug.

Months later, he lost vision in his other eye.

"If anyone had told me there's a possibility that this could happen, there is just no way that I would ever take that medication," Engel said.

Engel is now among thousands of patients suing Novo Nordisk and Eli Lilly, alleging they were not adequately warned about the risks of their blockbuster GLP-1 drugs.

For millions of patients, GLP-1 drugs have been safe and effective, delivering important health benefits for those struggling with obesity, diabetes, heart disease and more. But with many millions of people taking the drugs, some uncommon problems are coming to light.

I asked my friend Rich Weil, who's an exercise physiologist and certified diabetes educator, for his comments on this article. Longtime readers will recognize his name – I've shared his insights on weight-loss drugs a few times over the years. Rich has worked with thousands of obese patients through his business, Transformational Weight Control.

He replied that the man's risk factors were already high:

This patient had diabetes, so he had a roughly three times higher risk for blindness. We have no idea how long this patient had diabetes (length of time increases the risk) or what his blood sugar level was (another risk factor).

I cannot tell you how many patients I have seen with diabetes who are on a GLP-1 and two or even three other glucose-lowering agents, which can lead to hypoglycemia (low blood sugar) and blindness. Doctors need to monitor this and educate patients on the proper use of GLP-1s and how to eat while taking them.

The recent FDA warning on the risk of NAION when taking a GLP-1 is preposterous. More than a half dozen studies show there is no causation, only correlation, as patients prescribed GLP-1s have higher rates of diabetes, obesity, sleep apnea, and hypertension – all established risk factors for NAION. This is why the American Academy of Ophthalmology/North American Neuro-Ophthalmology Society says: "Causation has not been established... any added risk appears small... [patients should] not stop medication without talking to their doctor."

He concluded:

The worst part of all of this? More than 20 of my patients e-mailed me, worried about going blind. The irresponsible, misinformed, false, sensationalized, fatalistic headlines and stories about GLP-1s, with no accountability, fact checking, nor critical and analytical evaluation, only serve to scare people away from the most researched, safest, most efficacious, life-altering anti-obesity medication ever developed. And once it's on social media, forget it. That's the black hole of confirmation bias. All of this is just an abomination and has the real potential of harming people.

Thank you, Rich.

GLP-1 drugs aren't risk-free. No drugs are. The question is whether the benefits outweigh the risks...

My primary issue with articles like the one above is that they fail to highlight that obesity is one of the worst diseases you can have. It increases the chances of more than 200 diseases, ailments, and/or negative health outcomes – most alarmingly, the mega-killers: heart disease, diabetes, more than a dozen different types of cancer, and dementia.

Obesity also causes untold suffering with chronic conditions such as joint/hip/knee pain, sleep apnea, gout, exhaustion, etc. and dramatically shortens one's lifespan. Plus, it can have a horrible effect on one's mental health, relationships, and personal life.

If you told me I had to choose between smoking a pack of cigarettes a day or being obese for the rest of my life... I'd choose the former in a heartbeat.

I'm trying to help as many people as I can by sharing the benefits of these drugs, even at the risk of annoying some folks. These are uncomfortable conversations. But I would view myself as a lousy friend if I didn't encourage my overweight friends (and readers) to consider a drug that would address their chronic, long-term disease.

I've spent roughly five years obsessively studying these drugs and, as such, have developed an expertise that's valuable to people who are just hearing about the GLP-1s. I'm on a mission to proactively share that expertise with as many people as I can. If they're not interested, that's fine. If they're offended because I've crossed a line, forgive me.

I will gladly annoy 10 people if I can help one. And the good news: The actual ratio is the reverse!

Tying all of this back to investing... I remain bullish on Eli Lilly because it makes the best weight-loss drug (tirzepatide) – and has an even better one (retatrutide) in late-stage trials.

This is a class of drugs that roughly 10% to 12% of Americans are on, but 72% would benefit from. That's a huge addressable market... And it's not even considering the rest of the world's obese/overweight population or people who might choose to microdose these drugs for their other health benefits (like me).

That's a very long growth runway...

Best regards,

Whitney

P.S. I welcome your feedback – send me an e-mail by clicking here.

Recent Articles

View Full Archives
Subscribe to Whitney Tilson's Daily for FREE
Get the Whitney Tilson's Daily delivered straight to your inbox.

No spam pledge: We'll never rent, misuse or abuse your email address. By entering your e-mail, you will also begin receiving Whitney Tilson's Daily. You can unsubscribe from Whitney Tilson's Daily at any time. Privacy Policy.

About the Editor
Whitney Tilson
Whitney Tilson
Editor

Whitney is the Editor of Stansberry's Investment Advisory, Stansberry Research's flagship newsletter, The N.E.W. System, Commodity Supercycles, Whitney Tilson's Ultimate Upside, and Whitney Tilson's Daily. He is also a member of the Stansberry Portfolio Solutions Investment Committee.

Whitney spent nearly 20 years on Wall Street. During that time, he founded and ran Kase Capital Management, which managed three value-oriented hedge funds and two mutual funds. Starting out of his bedroom with $1 million, Whitney grew assets under management to a peak of $200 million.

Once dubbed "The Prophet" by CNBC, Whitney predicted the dot-com crash, the housing bust, the 2009 stock bottom, and more. An accomplished writer, Whitney has published four books, the most recent of which is The Art of Playing Defense: How to Get Ahead by Not Falling Behind (2021). And he contributed to Poor Charlie's Almanack: The Essential Wit and Wisdom of Charles T. Munger (2005), the definitive book on Berkshire Hathaway's Vice Chairman Charlie Munger.

Whitney has appeared dozens of times on CNBC, Bloomberg TV, and Fox Business Network, and has been profiled by the Wall Street Journal and the Washington Post. He has also written for Forbes, the Financial Times, Kiplinger's, the Motley Fool, and TheStreet.com.

Whitney graduated with honors from Harvard University, earning a bachelor's degree in government. Upon graduation, he helped Wendy Kopp launch the Teach for America program. He went on to earn his Master of Business Administration degree at Harvard in 1994. Whitney graduated in the top 5% of his class and was named a Baker Scholar.

Back to Top